Search Results 341-350 of 15892 for SC

  1. Meet Our Residents - General Surgery Residency (Florida) - Mayo Clinic College of Medicine & Science

    Jonathan Vandenberg, M.D.. Medical school: University of South Carolina. PGY-5. Class of 2027. Monica Mazur, M.D.. Monica Price, M.D.. Medical school: Rush ...

  2. Nonalcoholic Steatohepatitis Clinical Trials - Mayo Clinic Research

    ... (sc) to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) with no fibrosis to moderate fibrosis ...

  3. Michael B. Wallace, M.D. - Doctors and Medical Staff - Mayo Clinic

    He completed advanced endoscopic training at the Medical University of South Carolina under the mentor ship of Dr. ... South Carolina. 2001. MemberSearch ...

  4. Publications - Maria Alice V. Willrich, Ph.D. - Mayo Clinic

    ... SC, Sridharan M. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. Blood Adv. 2023 Feb ...

  5. Publications - Kevin C. Halling, M.D., Ph.D. - Mayo Clinic

    Gonzalez-Bosquet J, Shahi M, Yadav S, Kanwar N, Alvand S, Sosa C, Dowdy SC, Halling KC, Weroha SJ, Bakkum-Gamez JN, Podratz KC. ECPPF stratification ...

  6. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy - Mayo Clinic

    ... SC dose at Week 2 [or one 80 mg SC dose at Baseline, followed by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]); OR; At ...

  7. Judy C. Boughey, M.D. - Doctors and Medical Staff - Mayo Clinic

    ... South Carolina Chapter of the ACS, Charleston, SC. 2000. First Place Award, Resident Paper CompetitionSC-ACS Committee on Trauma, Greenville, SC. 1995. Henry ...

  8. Regenerative Nephrology Compassionate Use Program - Division of Nephrology and Hypertension - Mayo Clinic Research

    Saad A, Dietz AB, Herrmann SMS, Hickson LJ, Glockner JF, McKusick MA, Misra S, Bjarnason H, Armstrong AS, Gastineau DA, Lerman LO, Textor SC. Autologous ...

  9. A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 - Mayo Clinic

    ... (SC) for an additional 20 Weeks after completing the 32 Week study assessments post-randomization, while they continue with their background HES therapy per ...

  10. Publications - Kah Whye Peng, Ph.D. - Mayo Clinic

    ... SC, Rafael G, Tran S, Baum A, Kyratsous CA, Peng KW, Russell SJ. IMMUNO-COV ... Concilio SC, Russell SJ, Peng KW. A brief review of reporter gene ...